Health Studies MN

Within 


Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

3032 Study Matches

Sorting by: Relevance Distance

ROA2233: Pilot Study of PROS Monitoring

Pilot Study of PROS Monitoring

Allison Garda
Female
18 years and over
This study is NOT accepting healthy volunteers
2022-307933-H01-RST
22-004148
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Female, 18 years of age or older.
  • Women treated for breast cancer with radiation with a curative intent


Exclusion Criteria:

  • Non breast cancer.
  • Children under 18-years of age.
  • Non curative intent.

Eligibility last updated 4/19/22.  Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Obesity-Induced Dysfunction of Human MSC in Peripheral Microvascular Repair

Dysfunction of Mesenchymal Stem/Stromal Cells Induced by Obesity

Lilach Lerman
All
18 years to 80 years old
This study is NOT accepting healthy volunteers
2022-307980-H01-RST
22-004291
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Group 1:
    • Age 18-80 years;
    • BMI ≥ 35 kg/m^2;
    • Eligible for bariatric surgery;
    • Ability to provide consent.
  • Group 2:
    • Age 18-80 years;
    • BMI ≤ 30 kg/m^2;
    • Undergoing live donor nephrectomy;
    • Ability to provide consent.


Exclusion Criteria:
 

  • Pregnancy.
  • Chronic Inflammatory Disease (e.g., rheumatoid arthritis).
  • Active malignancy.
  • Recent stroke or myocardial infarction.
  • Solid organ transplant recipients.
  • Therapeutic doses of immunosuppressive drugs (including calcineurin inhibitors and prednisone (> 10 mg/day).
  • Senolytic supplements.
  • Subjects on therapeutic doses of anticoagulants [including Warfarin (Coumadin), Rivaroxaban (Xarleto); Apixaban (Eliquis); Dabigatran (Pradaxa, Prazaxa)].
  • Subjects deemed ineligible to comply with study protocol.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Evaluation of a Wearable Physiologic Monitor to Detect Sleep Quality

Evaluate Sleep Quality from Wearable Physiologic Monitor

Timothy Morgenthaler
All
19 years and over
This study is NOT accepting healthy volunteers
2022-308005-H01-RST
22-004369
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adults  > 18 years of age.
  • Body-Mass Index (BMI) < 35.
  • Normal sleep routine (typically awake during day and asleep at night).


Exclusion Criteria:
 

  • Prior diagnosis of, or positive STOP-BANG screen (> 3) for sleep apnea.
  • Excessive daytime sleepiness (the recorded Epworth Sleepiness Scale (ESS) must be ≤ 9).
  • History of heart failure, atrial fibrillation, pulmonary, neurological, or psychiatric disease.
  • Currently being treated pharmacologically for depression or other significant medical condition (broadly speaking).
  • Subject is receiving hypnotics or stimulant medication.
  • Habitual use of 3 or more cups of coffee/caffeinated tea per day.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Preliminary Evaluation of At-Home Self-Collection for Pre-Transplant Patients

At-Home Self-Collection for Pre-Transplant Patients

Manish Gandhi
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308101-H01-RST
22-004659
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult (≥ 18 years) pre-transplant kidney patient.


Exclusion Criteria:

  • Individuals < 18 years.
  • Not pre-transplant kidney patient.

Eligibility last updated 5/2/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Intracardiac Flow Assessment in Cardiac Amyloidosis

Intracardiac Flow Assessment in Cardiac Amyloidosis

Ian Chang
All
40 years and over
This study is NOT accepting healthy volunteers
2022-307150-H01-RST
22-001098
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- Subject is clinically stable without cardio-vascular-related hospitalizations within 6
weeks prior to enrollment as assessed by the investigators.

- Subject is able to provide written informed consent and is willing and able to
complete study procedures.

- Currently in sinus rhythm by clinical assessment or documented electrocardiographic
studies.

- Subject and disease characteristics noted by medical record review:

- Healthy control volunteers must also meet the following criteria: Karnofsky
performance scale > 80%; ECOG status 0 or 1.

- ATTRwt cardiac amyloidosis based on meeting all the following criteria: Diagnosis
of amyloidosis within two years prior to study screening; Documentation of
absence of pathogenic TTR mutation; Documentation of absence of plasma cell
dyscrasia, including monoclonal gammopathy of undetermined significance (MGUS) by
laboratory studies including serum free light chain assay and serum or urine
immunofixation; Amyloid deposits in cardiac tissue with TTR protein
identification by mass spectrometry or immuno-histochemistry, OR technetium
(99mTc) pyrophosphate scintigraphy with grade 2 or 3 cardiac uptake; Evidence of
cardiac involvement by echocardiography with an end-diastolic mean wall thickness
> 12 mm, OR CMR diagnostic of amyloidosis;

- AL with cardiac involvement based on meeting all the following criteria:
Diagnosis of amyloidosis within two years prior to study screening;
Histopathologic diagnosis of amyloidosis with AL protein identification by mass
spectrometry or immuno-histochemistry; Documented clinical signs and symptoms
consistent with heart failure in the absence of an alternative explanation;
Cardiac involvement as defined by: Amyloid deposits in cardiac deposits OR
Echocardiography with an end-diastolic mean wall thickness > 12 mm in the absence
of other causes OR Elevated NT-proBNP (>332 ng/L) in the absence of renal failure
or atrial fibrillation OR CMR diagnostic of amyloidosis;

- AL without cardiac involvement based on meeting all the following criteria:
Diagnosis of amyloidosis within two years prior to study screening;
Histopathologic diagnosis of amyloidosis with AL protein identification by mass
spectrometry or immuno-histochemistry; No documented clinical signs and symptoms
consistent with heart failure from AL; Absence of cardiac involvement as defined
by: Echocardiography with an end-diastolic mean wall thickness < 13 mm if the
subject does not have other causes for increased wall thickness AND NT-proBNP
<333 ng/L if the subject does not have renal failure or atrial fibrillation AND
No CMR diagnostic of amyloidosis if CMR is available prior to screening.


Exclusion Criteria:


- Unable to consent or unable to complete all study procedures.

- Unable to ambulate for 6 minutes (confirmed at study coordinator visit).

- Unable to maintain in supine position for 30 minutes.

- Unable to maintain breath-holding for 10 seconds (confirmed at study coordinator
visit).

- Contraindications for safe CMR scanning (e.g., claustrophobia, cochlear implant,
implanted neural stimulator).

- Presence of implantable cardiac pacemaker, defibrillator or recorder.

- History of intracardiac prosthesis, congenital heart disease, intracardiac shunt,
prior intrathoracic surgery, or procedures to the thoracic aorta or pulmonary
arteries.

- Significant artifact from prior MRI studies.

- Pregnant or breast-feeding women.

- Weight equal to or greater than 155 kg.

- Maximum body side-to-side or anterior-posterior diameter equal to or greater than 70
cm.

- Documented non-sinus rhythm within 6 months prior to screening.

- For healthy controls, the following exclusion criteria apply, confirmed per chart
review and/or patient report:

- History of cardiomyopathy or structural heart disease;

- History of valvular disease of greater than mild severity;

- History of coronary artery disease or coronary heart disease;

- History of cardiac or thoracic surgery.

- History of atrial tachyarrhythmia, ventricular tachyarrhythmia, or symptomatic
bradyarrhythmia;

- Left ventricular hypertrophy or abnormally increased myocardial thickness by
prior echocardiography, cardiac computed tomography, or CMR;

- Acute kidney injury, OR chronic renal disease with glomerular filtration rate <
60 mL/min/1.73m^2 as per medical record review.

- Uncontrolled hypertension of systolic blood pressure > 140 mmHg or diastolic
blood pressure > 90 mmHg as per medical record review;

- Taking two or more anti-hypertensive medications;

- Type 1 diabetes, OR uncontrolled type 2 diabetes mellitus of hemoglobin A1c
greater than 7, as per medical record review;

- Taking two or more diabetic medications;

- History of stroke or transient ischemic attack;

- Current cigarette smoker;

- History of peripheral artery disease of aortopathy;

- History of plasma cell dyscrasia or chronic hematologic diagnosis;

- BMI > 35 kg/m^2.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 8/3/22. Questions regarding updates should be directed to the study team contact

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Focal Prostate Ablation for Intermediate Grade Cancer Utilizing TULSA Profound System

Focal Prostate Ablation Utilizing TULSA Profound System

David Woodrum
Male
45 years to 80 years old
Not Applicable
This study is NOT accepting healthy volunteers
2022-307169-P01-RST
22-001336
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male patients.
  • Age 45-80 years, with > 10 years life expectancy.
  • Biopsy-confirmed, NCCN (favorable GG2 and unfavorable GG3) intermediate-risk prostate cancer.
  • Stage ≤ T2c, N0, M0.
  • ISUP Grade Group 2 or 3 disease on TRUS-guided biopsy (minimum 8 cores, combination of systematic and MRI fusion-guided) or in-bore biopsy (minimum 3 cores from each PI-RADS v2 category ≥ 3 lesion). Biopsy reported within 12 months of baseline visit, with minimum 6-week interval between biopsy and baseline.
  • PSA ≤ 20 ng/mL reported within 3 months of baseline.
  • Treatment naïve.
  • Planned ablation volume < 3.0 cm axial radius from the urethra on mpMRI acquired within 6 months of baseline.  


Exclusion Criteria:

  • Inability to undergo MRI or general anaesthesia.
  • Suspected tumour > 30 mm from the prostatic urethra.
  • Prostate calcifications > 3 mm in maximum extent obstructing ablation of tumour on low-dose pelvic CT:                
    • Criteria subject to additional review and approval by sponsor. Alternatively, prospective TRUS to query calcifications or susceptibility-weighted MRI if available may be used to assess calcifications. Imaging for calcification screening must be dated within 1 year of baseline visit.
  • Unresolved urinary tract infection or prostatitis.
  • History of proctitis, bladder stones, hematuria, history of acute urinary retention, severe neurogenic bladder.
  • Artificial urinary sphincter, penile implant or intraprostatic implant.
  • Less than 10 years life expectancy.
  • Patients who are otherwise not deemed candidates for RP.
  • Inability or unwillingness to provide informed consent.
  • History of anal or rectal fibrosis or stenosis, or urethral stenosis, or other abnormality challenging insertion of devices.

Eligibility last updated 2/7/22. Questions regarding updates should be directed to the study team contact.

 

Procedure/Surgery
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Placental inflammation and function – in vitro analysis

Placenta Study

Sylvie Girard
Female
18 years to 50 years old
This study is NOT accepting healthy volunteers
2022-307202-H01-RST
22-000892
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Women who will give birth at Mayo Clinic by caesarean-section at term following an uncomplicated pregnancy.


Exclusion Criteria:

  • Multiple pregnancy.
  • Known presence of clinical infections (e.g., chorioamnionitis), congenital anomalies or maternal pathologies (i.e., diabetes, hypertension, preeclampsia).
  • Intrauterine growth retardation or fetal macrosomia.
  • Maternal age under 18 or over 50.
  • Maternal body mass index (BMI) of less than 18 and more than 40.
  • Pregnancy less than 37 weeks of completed gestation.

Eligibility last updated 2/2/22. Questions regarding updates should be directed to the study team contact.

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Post-market Study for Continuing Evaluation and Periodic Reporting of the Safety and Effectiveness of the Spatz3 Intragastric Balloon (PAS-S)

Spatz3 Adjustable Balloon System® (Spatz3) Post Approval Study

Barham Abu Dayyeh
All
22 years to 65 years old
Post Market
This study is NOT accepting healthy volunteers
2022-307203-P01-RST
22-001232
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age 22
    •65 years.
  • BMI ≥ 35 and < 40 kg/m^2 or BMI of 30 to 34.9 kg/m^2 with one or more major obesity-related comorbid conditions.
  • Willingness to comply with the substantial lifelong dietary restrictions required by the procedure.
  • History of obesity (BMI ≥ 30) for at least 2 years.
  • History of failure with non-surgical weight loss methods.
  • Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory tests, completing diet counseling.
  • Residing within a reasonable distance from the investigator’s office and able to travel to the investigator to complete all routine follow-up visits.
  • Ability to give informed consent.
  • Women of childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods.  Acceptable birth control methods are limited to hormonal contraceptives (oral, flexible vaginal ring, skin patch, injection), diaphragms, IUDs, condoms with or without spermicide, and voluntary abstinence.  Should a treatment arm subject become pregnant during the implantation period, the balloon will be extracted during the second trimester
    •the timing of which will be determined via consultation with the subject’s obstetrician.


Exclusion Criteria:

  • Prior surgery involving the esophagus, stomach, and duodenum or bariatric surgery.
  • Prior open or laparoscopic bariatric surgery.
  • Prior surgery of any kind on the esophagus, stomach, duodenum or any type of hiatal hernia surgery.
  • Any inflammatory disease of the gastrointestinal tract including esophagitis, Barrett’s esophagus, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn’s disease
  • Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses.
  • A gastric mass.
  • A hiatal hernia > 2cm or severe or intractable gastro-esophageal reflux symptoms.
  • Acid reflux symptoms to any degree that require more than one medication for symptom control.
  • A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the balloon alongside the endoscope.
  • Achalasia or any other severe esophageal motility disorder that may pose a safety risk during the removal of the device.
  • Severe coagulopathy.
  • Insulin-dependent diabetes (either Type 1 or Type 2) or a significant likelihood of requiring insulin treatment in the following 12 months.
  • Subjects with any serious health condition unrelated to their weight that would increase the risk of endoscopy.
  • Chronic abdominal pain.
  • Motility disorders of the GI tract such as gross esophageal motility disorders, gastroparesis or intractable constipation.
  • Hepatic insufficiency or cirrhosis.
  • Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with follow up visits and removal of the device after 8 months.
  • Alcoholism or drug addiction.
  • Patients unwilling to participate in an established medically-supervised diet and behavior modification program, with routine medical follow-up.
  • Patients receiving daily prescribed treatment with aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants.
  • Patients who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.
  • Patients who are known to have, or suspected to have, an allergic reaction to materials contained in the system.
  • Patients who have BOTH:
    • A previous history of a serotonin syndrome; AND
    • currently taking any drug known to affect the levels of serotonin in the body [e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs)].
  • Patients who are pregnant or breast-feeding.
  • Subjects with severe cardiopulmonary disease or other serious organic disease which might include known history of coronary artery disease, myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs.
  • Subjects who have tested positive for H. Pylori, and who have not yet been treated.

Eligibility last updated 2/3/22. Questions regarding updates should be directed to the study team contact.

Device
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

T-cell Clonality in Rheumatoid Arthritis (SMRA)

Somatic Mutation in Rheumatoid Arthritis

Jorg Goronzy
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307251-H01-RST
22-001428
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Diagnosis of seropositive rheumatoid arthritis (either Rheumatoid factor or anti-CCP positive).
  • Age-matched Healthy Controls.


Exclusion Criteria:

  • Chronic active viral infection.
  • History of chemo/radiotherapy.
  • History of cancer.
  • Other autoimmune disease.
  • Pregnancy.

Eligibility last updated 3/23/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Irina Bancos
All
18 years and over
Phase 2
This study is NOT accepting healthy volunteers
2022-307253-P01-RST
22-001433
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:
 

  • Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome with at least 80% compliance with the dosing schedule.
  • According to the Investigator's opinion, will benefit from continuing treatment with relacorilant.


Exclusion Criteria:

  • Premature discontinuation from a relacorilant parent study.
  • Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
  • Has poorly controlled hypertension.
  • Has Stage ≥ 4 renal failure.

Eligibility last updated 2/8/22. Questions regarding updates should be directed to the study team contact.

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Transcatheter Pulmonary Valve Replacement and Catheter Ablation of Ventricular Tachycardia in Tetralogy of Fallot

Transcatheter Pulmonary Valve Replacement and Catheter Ablation of Ventricular Tachycardia in Tetralogy of Fallot

Christopher McLeod
All
18 years and over
This study is NOT accepting healthy volunteers
2022-306992-P01-RST
22-000295
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients with TOF or TOF-related variants.
  • Age ≥ 18 years.
  • Planned transcatheter valve placement in native RVOT.


Exclusion Criteria:

  • Individuals < 18 years.
  • Non-TOF related variants (i.e., pulmonary stenosis, PA-IVS, etc.).
  • Prior catheter or surgical ablation of ventricular tachycardia (VT).

Eligibility last updated 1/24/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Minnesota Regional SCIMS (SCIMS)

Spinal Cord Injury Model Systems for Minnesota Region (SCIMS)

Ronald Reeves
All
18 years and over
This study is NOT accepting healthy volunteers
2022-306996-P01-RST
22-000795
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Presence of an external traumatic event that results in a spinal cord injury, including surgical procedures, radiation, and medical complications.
  • Temporary or permanent loss of sensory and/or motor function as a result of the traumatic event.
  •  Admission to the system within one year of injury.
  • Discharge from the System Rehab as:
    • Having completed inpatient acute rehabilitation;
    • Deceased.
  • Signed informed consent and HIPAA authorization forms.
  • Reside in the geographic catchment area of the system at the time of the injury.  Patients may be injured outside of the catchment area.
  • A US citizen or non-US citizen who is expected to stay in the catchment area.


Exclusion Criteria:

  • Must not have previously been treated at another model system for the injury.
    • Ensures that patients are enrolled into the database by only one model system.
  • Must not have completed an organized rehabilitation program prior to the admission to the system.

Eligibility last updated 1/24/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Pushing the Envelope in Reduction of Hysterectomy Surgical Site Infection (SSI): Studying the role of an Anal Occlusive Dressing (AOD) (AOD and SSI)

Anal Occlusion and SSI Reduction

Tarek Khalife
Female
18 years to 65 years old
This study is NOT accepting healthy volunteers
2022-307005-H01-MAIJ
22-000637
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients subject to a laparoscopic hysterectomy procedure necessitating uterine manipulator use,
  • Age 18-65.


Exclusion Criteria:

  • Patient known to have a vesicovaginal or rectovaginal fistula.
  • Patients who have a documented tape allergy.
  • Patients know to have an active pelvic infection.
  • Patient diagnosed or known to have fecal incontinence.
  • Patients diagnosed or known to have severe external hemorrhoids.
  • Patients with a very short perineal body with < 2cm.
  • Patients who were found to have a disruption in the occlusive dressing seal at the end of the case (blood soilage).
  • Patients necessitating a rectal exam or manipulation as part of the procedure.
  • Patient with visible skin irritation or inflammation around the anal orifice.

Eligibility last updated 2/14/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic Health System — Mankato, MN

Assessing the Experiences of LGBTQ patients in the ICU (LGBT in ICU)

Assessing the Experiences of LGBTQ Patients in the ICU

Erin DeMartino
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307009-H01-RST
22-000846
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Is 18 years old or older.
  • Self-identifies as a member of the LGBTQ community or self-identified as such at the time of their admission or is the spouse, partner, or family member who identifies as a member of the LGBTQ community.
  • Has been on a ventilator in the intensive care unit or is the spouse, partner, or family member of a patient on a ventilator in the intensive care unit between 1/2016 and 2/2022.


Exclusion Criteria:
 

  • Does not meet the above criteria for age, LGBTQ identity, relationship to an LGBTQ identifying individual, and past mechanical ventilation.

Eligibility last updated 3/2/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

The Development of a Shared Decision-Making Encounter Tool for Decisions of Adjuvant Treatment in Patients with Resected Non-Small Cell Lung Cancer (NSCLC)

Shared Decision-Making Encounter Tool for Decisions of Adjuvant Treatment in Patients with Resected Non-Small Cell Lung Cancer

Konstantinos Leventakos
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307019-P01-RST
21-013359
Show full eligibility criteria
Hide eligibility criteria

Patient

Inclusion Criteria:

  • Adults ≥ 18 years with biopsy proven resected NSCLC.
  • Appointment to discuss adjuvant treatment of resected NSCLC.

Patient


Exclusion Criteria:

  • Major barriers to providing informed consent (i.e. dementia, severe hearing or visual impairment).

Clinician

Inclusion Criteria:

  • Clinicians who meet with patients to discuss adjuvant treatment of resected NSCLC.

Clinician


Exclusion Criteria:

  • None.

PAG Member

Inclusion Criteria:

  • Adults ≥ 18 years.
  • Member of the KER Unit PAG.

PAG Member


Exclusion Criteria:

  • None.

Eligibility last updated 1/28/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Prospective Observational Study Assessing Efficacy of 10-kHz Spinal Cord Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Spinal Cord Stimulation to Treat Chemotherapy-Induced Peripheral Neuropathy

Ryan D'Souza
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307074-P01-RST
22-001218
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- Adult patients aged 18 to 70 who have been clinically diagnosed with CIPN for greater
than six months after stopping chemotherapy

- Average pain intensity >= 5 on 11-point numeric rating scale (NRS) in the lower
extremities at enrollment

- Failed conventional medication management with at least two neuropathic pain
medications

- Have electrophysiological evidence of length-dependent peripheral neuropathy

- Underwent a 10-kHz spinal cord stimulator trial for a primary indication of CIPN and
reported a successful trial of at least 75% reduction in pain intensity

- Have stable neurological status

- Be on a stable analgesic regimen

- Be an appropriate candidate for surgical procedures required in this study

- Be able to read and understand English-written questionnaires and sign an informed
consent form in English

- Be willing and capable of giving informed consent

- Be willing and able to complete study-related requirements, procedures, and visits


Exclusion Criteria:


- Patient refusal to be included in study

- Presence of lower limb mononeuropathy

- History of lower limb amputation or ulceration

- Presence of another painful condition that is unrelated to CIPN and that is not
intended to be treated in this study

- Body mass index (BMI) >= 40

- Omeprazole (OME) > 120 mg

- Progressive neurological disease (multiple sclerosis, chronic inflammatory
demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord
tumor, central deafferentation syndrome, complex regional pain syndrome, acute
herniating disc, severe spinal stenosis)

- Certain comorbidities: coagulation/bleeding disorders, diminished capacity from
cardiac/pulmonary disease

- Obtaining another interventional procedure unrelated to SCS to treat limb pain

- Have ongoing metastatic malignant neoplasm or untreated local malignant neoplasm.
Included patients must be deemed as in remission per discretion of treating oncologist

- Have a life expectancy of less than one year

- Have untreated addiction or dependency to medications, alcohol, or illicit drugs

- Have active, disruptive, and/or unstable psychological or psychiatric disorder

Eligibility last updated 8/9/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Normative Biomechanical Measures of Reaching in Able-Bodied Adults

Reach Normal Controls

Kristin Zhao
All
20 years to 59 years old
Not Applicable
This study is NOT accepting healthy volunteers
2022-307103-H01-RST
22-000958
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- 20-59 years of age at time of enrollment


Exclusion Criteria:


- Failure to give consent or follow simple commands

- Score of 7 or above on the QuickDASH Outcome Measure

- Score of 5 or above on the Oswestry Low Back Disability Questionnaire

- Score of 76 or below on the Lower Extremity Functional Scale

- Diagnosis of a neuromuscular disorder (e.g., muscular dystrophy, multiple sclerosis,
fibromyalgia)

- Diagnosis of an inner ear balance disorder (e.g., benign paroxysmal positional
vertigo)

- Insufficient active range of motion of bilateral shoulders or hips that results in
inability to perform forward or lateral reaching tasks

- Any illness or condition which, based on the research team's assessment, will
compromise the patient's ability to comply with the protocol, patient safety, or the
validity of the data collected during this study

Eligibility last updated 7/14/22. Questions regarding updates should be directed to the study team contact.

Other, Functional reach test
Finding related to ability to reach
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Autotransfusion During Intralesional Tumor Resection: Effectiveness of Leukocyte Reduction Filtration in Removing Neoplastic Cells (CSDTR)

Cell Saver During Tumor Resection

Matthew Houdek
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307110-H01-RST
22-000975
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Any patient undergoing surgery for intralesional resection of neoplasm such as tumors of the spine/extremities or metastatic disease.


Exclusion Criteria:

  • Patients undergoing surgery with an expected blood loss of less than 135cc.
  • Provisions for inclusion of minorities: 
    • Subjects will be enrolled prospectively irrespective of their sex/gender, race, and ethnicity in order to improve generalizability.        

Eligibility last updated 2/21/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Heart Failure (HF) Clinic Biobank

Heart Failure (HF) Clinic Biobank

Horng Chen
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307126-H01-RST
22-000991
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients referred to the Mayo Clinic HF Clinic with a diagnosis of heart failure who have a clinical blood draw scheduled.
  • Adults ≥ 18 years old.


Exclusion Criteria:

  • Individuals < 18 years old.
  • Any history of Hemoglobin less than 9 mg/dL during the past 3 months.
  • Active cancer.

Eligibility last updated 1/28/22. Questions regarding updates should be directed to the study team contact.

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence with Natera (cfDNA with Natera)

cfDNA with Natera

Shanda Blackmon
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307127-P01-RST
22-001607
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Esophageal cancer any stage.
  • Age ≥ 18 years old.
  • Willing and able to provide consent.
  • No prior history of neoadjuvant therapy for the esophageal cancer.


Exclusion Criteria:
 

  • Age < 18 years old.
  • Unable to provide consent.

Eligibility last updated 2/11/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) (GAIN)

Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) (GAIN)

Cadman Leggett
All
45 years to 80 years old
Not Applicable
This study is NOT accepting healthy volunteers
2022-307142-P01-RST
22-001278
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:
 

  • Scheduled to undergo routine screening (including, but not limited to, FIT/Cologuard positive), routine surveillance (≥ years as scheduled since last colonoscopy), or diagnostic (symptomatic) colonoscopy with High Definition White Light Endoscopy.
  • Between the ages of 45 and 80 years, inclusive.
  • Able and willing to provide written informed consent.


Exclusion Criteria:

  • Self-reported pregnancy.
  • Known diagnosis of Colorectal Cancer.
  • History of, or referral for, Inflammatory Bowel Disease.
  • Previous surgery involving the colon or rectum.
  • Referral for known polyp or assessment of post-polypectomy site (i.e. less than 3 years since last colonoscopy).
  • High suspicion or diagnosis of genetic polyposis syndromes, including familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), or any other high-risk family history meeting Bethesda guidelines.
  • Referral for overt, symptomatic gastrointestinal bleeding.

Eligibility last updated 2/4/22. Questions regarding updates should be directed to the study team contact.

Device
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Molecular Breast Imaging (MBI) Patient Survey

Patient Survey of Molecular Breast Imaging

Carrie Hruska
Female
21 years and over
This study is NOT accepting healthy volunteers
2022-308388-H01-RST
22-006013
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Female.
  • MBI exam performed at Mayo Clinic in Rochester, MN.
  • Email address provided in the medical record.


Exclusion Criteria:

  • Protected research populations (pregnant women, prisoners, children, and adults lacking capacity to consent) will not be included in the study.

Eligibility last updated 6/7/22. Questions regarding updates should be directed to the study team contact.

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Molecular prediction of Helicobacter pylori antimicrobial resistance patterns

Helicobacter Pylori Antimicrobial Resistance Patterns Using Molecular Prediction

Robin Patel
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308424-H01-RST
22-005955
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  •  ≥  18 years of age. 
  • Suspected of having a H. pylori infection and are undergoing or recently have undergone a gastric biopsy.


Exclusion Criteria:

  • On a current antibiotic regimen and negative for H. pylori as tested from a gastric biopsy.

Eligibility last updated 9/8/22. Questions regarding updates should be directed to the study team contact.

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Mobile Application Based Lactulose Titration for Prevention of Hepatic Encephalopathy

Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration

Douglas Simonetto
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2022-308598-H01-RST
22-006646
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients over the age of 18 years.
  • Ability to provide written, informed consent.
  • Currently taking lactulose daily for prevention of hepatic encephalopathy.

Exclusion Criteria:

  • Recent change in dosing of opioid medication.
  • Previous Colorectal Surgery.
  • Active diarrheal illness.
  • Lack of smartphone or other smart device at home.

Eligibility last updated 7/8/22. Questions regarding updates should be directed to the study team contact.

 

Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Accuracy of Non-invasive Hemoglobin Monitoring in Patients Undergoing Outpatient Total Joint Arthroplasty

Non-invasive Hemoglobin Monitoring in Patients Undergoing Outpatient TJA

Matthew Abdel
All
18 years and over
This study is NOT accepting healthy volunteers
2022-306974-H01-RST
22-000012
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult patients age ≥ 18.
  • Undergoing either primary total knee or total hip arthroplasty for a primary underlying diagnosis of osteoarthritis.


Exclusion Criteria:

  • Individuals < 18 years of age.

Eligibility last updated 1/21/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer (MNCCTN023)

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

Stephan Thome
Female
18 years and over
This study is NOT accepting healthy volunteers
2022-306982-P01-MAIJ
22-000839
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Ability to read and write in English.
  • Women with newly diagnosed with ovarian, primary peritoneal, or fallopian tube cancer.
  • Treatment plan includes chemotherapy.
  • Able to provide written voluntary consent before performance of any study related procedure.
  • Aim 1 only: after completion of initial chemotherapy.
  • Aim 2 only: prior to starting chemotherapy.


Exclusion Criteria:

  • Inability to provide informed consent.
  • Exposure to chemotherapy prior to ovarian cancer diagnosis.
  • Life expectancy < 3 months or in hospice care or nursing home.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic Health System — Mankato, MN

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer (MNCCTN023)

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

Mina Hanna
Female
18 years and over
This study is NOT accepting healthy volunteers
2022-306982-P01-ALCL
22-000839
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Ability to read and write in English.
  • Women with newly diagnosed with ovarian, primary peritoneal, or fallopian tube cancer.
  • Treatment plan includes chemotherapy.
  • Able to provide written voluntary consent before performance of any study related procedure.
  • Aim 1 only: after completion of initial chemotherapy.
  • Aim 2 only: prior to starting chemotherapy.


Exclusion Criteria:

  • Inability to provide informed consent.
  • Exposure to chemotherapy prior to ovarian cancer diagnosis.
  • Life expectancy < 3 months or in hospice care or nursing home.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic Health System — Albert Lea, MN

GRASP-IBD (GI and Rheumatology Assessment of Spondyloarthritis in Inflammatory Bowel Disease) (GRASP-IBD)

GI and Rheumatology Assessment of Spondyloarthritis in Inflammatory Bowel Disease

John Davis
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308107-H01-RST
22-004690
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult patients, ages 18-70 years.
  • Patients with Irritable Bowel Disease (IBD).


Exclusion Criteria:

  • Patients < 18 and over 70 years of age.

Eligibility last updated 5/2/22. Questions regarding updates should be directed to the study team contact.

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Review of Midgut Malrotation in the Adult Population: Diagnosis, Techniques and Outcomes of the Laparoscopic Ladd’s Procedure

Diagnosis, Techniques and Outcomes of the Laparoscopic Ladd’s Procedure: A Review of Midgut Malrotation

William Perry
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308114-H01-RST
22-004723
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients who underwent Ladd’s procedure. 


Exclusion Criteria:
  

  • < 18 years of age.

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Vitamin D-Sulfates in Breastmilk

Study of Breastmilk With Vitamin D-Sulfates

Thomas Thacher
Female
18 years and over
This study is NOT accepting healthy volunteers
2022-308273-H01-RST
22-005324
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Lactating women.
  • ≥ 2 weeks after delivery.
  • No intentions of weaning during the study.


Exclusion Criteria:
 

  • History of sarcoidosis.
  • History of renal disease.
  • Premature birth.
  • Taking daily supplement with ≥ 600 IU vitamin D in the past 30 days (accounting for washout period).
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN